This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
1 Dec 2014

Innova Biosciences Introduces Lightning-Link Rapid Bioconjugation Kits

Innova Biosciences, a specialist provider of bioconjugation products and services, has launched new antibody and protein labelling kits within its Lightning-Link Rapid range. These kits enable researchers to label primary antibodies or other proteins in just 20 minutes.

 

Dyes recently launched within this range include high sensitivity Atto dyes and Cy dyes. Innova has also released a rapid biotin conjugation kit which allows for extremely quick protein biotinylation. Despite the short incubation time, the conjugation reaction is sufficient to achieve conjugates with performance characteristics identical to, or better than, those prepared with laborious multistep conjugation procedures.

 

Lightning-Link is an innovative technology that enables direct labelling of antibodies, proteins, peptides or other biomolecules for use in R&D applications, drug discovery and the development of diagnostic kits. The procedure is easy to use, involves only 30 seconds of hands-on time, and no spin or separation steps are required. In addition, by circumventing the desalting or dialysis steps that commonly interrupt traditional protein labelling procedures, Lightning-Link Rapid technology can be used to label small quantities of antibody with 100% recovery.

 

Dr Nick Gee, CEO at Innova, said: "The launch of the Lightning-Link kits completes the development of our Rapid conjugation range, and follows on from the success of the original kits, which had a much longer reaction time. This latest product introduction underlines Lightning-Link as one of the world’s leading bioconjugation technologies, offering easy-to-use labelling that provides excellent results with minimal hands on time and 100% yield.”

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.